Companies › DRMA

Dermata Therapeutics Inc (DRMA)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001853816 · EDGAR filings · Updated 2026-06-16

Dermata Therapeutics Inc (DRMA) has reported institutional ownership of 2.6%, with 7 institutional managers holding positions valued at $128.9K per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.

Latest updates

• 2026-06-16 — Insider transaction reported (Form 4)
• 2026-06-04 — Employee-plan registration (S-8) filed
• 2026-06-01 — SCHEDULE 13D filed
• 2026-05-29 — EFFECT filed
• 2026-05-29 — Prospectus supplement (424B3) filed
• 2026-05-27 — Current report (8-K) filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, Dermata Therapeutics Inc has 7 institutional holders and institutional ownership of 2.6%.

Insider activity

Insiders reported 4 transactions (1 buys, 0 sells) across 3 reporting insiders, with a net reported value of $1.27K.

Data flags from SEC filings

Related companies

SONOMA PHARMACEUTICALS INC (SNOA) · VivoSim Labs Inc (VIVS) · CHINA SXT PHARMACEUTICALS IN (SXTC) · Indaptus Therapeutics Inc (INDP) · Sunshine Biopharma Inc (SBFM) · AZITRA INC (AZTR)